Pfizer Inc. (PFE) Announces Submission Of Biologics License Application To The FDA For Investigational Meningococcal B Vaccine
6/17/2014 10:30:33 AM
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for bivalent recombinant LP2086 (rLP2086), the company’s vaccine candidate for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 to 25 year olds.
Help employers find you! Check out all the jobs and post your resume.
comments powered by